



## ASX Release

### June 2016 Appendix 4C

**20 July 2016, Melbourne, Australia:** Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to provide the following Appendix 4C in relation to the quarter ended 30 June 2016.

#### Cash at 30 June 2016

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$9.75 million. The Company continues to manage operational expenditure carefully.

The increase in cash reserves during the quarter followed a successful capital raising of \$7 million through a Placement to professional and sophisticated investors and the acceptance of Entitlement shares, through the Company's Entitlement Offer to shareholders, amounting to \$2.04 million.

Subsequent to 30 June 2016, the Company successfully placed the remaining shortfall from its Entitlement issue, raising an additional \$1.35 million. This brings total proceeds from the Placement and Entitlement Offer to \$10.4 million, before costs.

#### Key activities during the quarter

During the quarter, the Company announced that Yale Cancer Center (**Yale**) in New Haven, Connecticut, USA, will join PTX's Phase 1b/2 clinical trial in acute myeloid leukemia (**AML**), which is shortly expected to recruit its first patient at the Moffitt Cancer Centre (**Moffitt**) in Florida.

The clinical trial will be undertaken with PTX's novel Akt inhibitor PTX-200 plus cytarabine in refractory or relapsed acute leukemias. Approximately 18 patients will be recruited in the Phase 1b component of the trial.

Yale Cancer Center is one of the 45 designated National Cancer Institute (**NCI**) comprehensive cancer centres in the US. These centers play a vital role in reducing morbidity and mortality from cancer through scientific research, cancer prevention and innovative cancer treatment.

#### **About Prescient Therapeutics Limited (PTX)**

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.

The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.




PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

**Further enquiries:**

Steven Yatomi-Clarke  
CEO & Managing Director  
Prescient Therapeutics Limited  
+61 417 601 440



# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/2010

Name of entity

Prescient Therapeutics Limited

ABN

56 006 569 106

Quarter ended ("current quarter")

30 June 2016

### Consolidated statement of cash flows

<b>Cash flows related to operating activities</b>	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) staff costs	(278)	(788)
(b) advertising and marketing	(3)	(38)
(c) research and development	(231)	(703)
(d) leased assets	-	-
(e) other working capital	(370)	(1,212)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	4	10
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other items		
(a) Net GST (paid to)/recovered from ATO	-	113
(b) R & D tax rebate received	-	559
(c) Government grant received	-	-
(d) R&D contract contributions received	-	-
<b>Net operating cash flows</b>	<b>(878)</b>	<b>(2,059)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	(878)	(2,059)
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
<b>Net investing cash flows</b>	-	-
<b>1.14 Total operating and investing cash flows</b>	(878)	(2,059)
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.	9,041	11,011
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Capital raising costs	(33)	(235)
<b>Net financing cash flows</b>	9,008	10,776
<b>Net increase (decrease) in cash held</b>	8,130	8,717
1.21 Cash at beginning of quarter/year to date	1,680	1,043
Exchange rate adjustments to item 1.20	(57)	(7)
1.23 <b>Cash at end of quarter</b>	9,753	9,753

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	161
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Directors' fees and Executive Directors' salaries paid during the June 2016 quarter.
--

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

-
---

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-
---

**Financing facilities available**

*Add notes as necessary for an understanding of the position.*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	9,733	1,660
4.2	Deposits at call	20	20
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)		9,753	1,680

**Acquisitions and disposals of business entities**


	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	-
5.2	Place of incorporation or registration	-
5.3	Consideration for acquisition or disposal	-
5.4	Total net assets	-
5.5	Nature of business	-

---

+ See chapter 19 for defined terms.

## Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:  \_\_\_\_\_ Date: 20 July 2016  
(Company Secretary)

Print name: Melanie Leydin

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirement requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.